Report From: India - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Report From: India
Pharmaceutical companies in India have had a hold on the biotechnology sector for many years, and they're not about to let the follow-on biologics market pass them by.

Pharmaceutical Technology
Volume 33, Issue 10, pp. 18-28

Regulatory challenges

Despite World Trade Organization membership and recent improvements in compliance with international regulatory and intellectual property laws, there remains no formal regulatory framework for follow-on biologics in India or China. "The market is highly fragmented and the many shifts in regulation have made it worse," says Shaw. "However, the opening up of the US market should drive growth in the sector.''

Currently, Asia is the primary market for follow-on biologics, accounting for 34.1% of global sales, according to a new report by Markets & Markets on Biosimilars (2009–2014), but the US market is predicted to rise to the top spot once a regulatory pathway for follow-on biologics approval is passed (At press time, several proposals were routing through the US Congress). According to the report, the sector is poised to be worth $19.4 billion by 2014 globally, by which time the US would have overtaken Asia as the dominant market.

Several follow-on biologic companies such as Biocon, Dr. Reddy's Laboratories (Hyderabad), Reliance LifeSciences (Mumbai), the Indian operation of San doz (Mumbai), Teva (Mumbai), and Wockhardt (Mumbai), are chaffing at the bit at the shifts in regulation. These firms have been marketing their drugs in India, China, and Europe for several years. Europe, which incorporated a regulatory approval pathway for follow-on biologics in 2004, has approved nine products to date.

The scientific and regulatory experiences with these products suggests that these firms are poised to dominate the US market after legislation permitting approval and sale of follow-on biologics is completed. "We would certainly like to have a first-mover advantage in the USA, as soon as the country opens its market for biogenerics,'' adds Pankaj Patel, CEO of the Zydus Cadila Group (Ahmedabad).

Zydus is developing follow-on therapeutic proteins and new biological entities, including monoclonal antibodies (mAbs), at its research center in Ahmedabad. Patel added that it is becoming increasingly apparent that "only large, well-capitalized companies with sophisticated regulatory, marketing, and distribution capabilities will be able to compete in the US follow-on biologics market. Several Indian companies fit the bill.'' Zydus's current follow-on biologic portfolio includes ESAs, interferons, insulin, growth factors, pegylated proteins, and mAbs.

Maintaining a lead

Table I: Select Indian pharmaceutical firms with follow-on biologics.
By 2015, follow-on biologic erythropoietins are expected to emerge as the dominant type of drug product around the world and achieve sales of $6.1 billion; close behind will be recombinant non-glycosylated protein products, which currently account for 61% of the global follow-on biologics market, according to the Markets & Markets report. Together, these products would help the global sector grow to $11.5 billion in sales, by 2015, according to the report. Indian firms, who already market erythropoietin drugs, are clearly in an advantageous position (see Table I).

Indian companies are taking on new vaccine-development challenges as well to maintain their edge in the biopharmaceutical sector. Some novel homegrown products in late-stage development include a single or combination vaccine against locally relevant diseases such as Japanese encephalitis and anthrax, cholera, and meningitis, manufactured by biopharmaceutical companies Panacea Biotec, Biological E (Hyderabad), and Transgene Biotek (Medak District, Andhra Pradesh), respectively, and a vaccine against rotaviral diarrhea (Bharat Biotech International, Hyderabad). Novel products such as bacteriophages as antibacterial agents against multidrug resistant bacteria and lysostaphin, an anti-infective multidrug resistant to Staphylococcus aureus, are also being developed in India.

To maintain a leadership position in follow-on biologics, Indian pharmaceutical and biotechnology companies are forming new alliances with the government-funded Department of Biotechnology, publicly funded institutions, and global philanthropic institutions such as the PATH Malaria Vaccine Initiative (a grantee of the Bill & Melinda Gates Foundation,) and the Wellcome Trust in the United Kingdom. The potential for further growth in follow-on biologics is huge, and Indian firms are solidifying their share of the pie.

A. Nair is a freelance writer based in Mumbai.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here